Eureka Aventis Labs Limited
About Eureka Aventis Labs Limited
Data last updated:
Eureka Aventis Labs Limited is a public limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 October 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2005PLC142039.
The company has an authorised share capital of ₹25 Lakh and a paid-up capital of ₹20 Lakh. It is led by directors including Manish Kumar Agarwal and Nishant Garg.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at GF – 02 (Groundfloor) Eurekahouse A – 30/2 Westjyotinagar Shahdara, Delhi, India – 110094.
As per the financials filed for FY 2025, the company reported a revenue of ₹65,000. For the same year it recorded a net profit of ₹32,860 (net margin 50.6%) and EBITDA of ₹44,660 (EBITDA margin 68.7%).
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Eureka Aventis Labs Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressGF – 02 (Groundfloor) Eurekahouse A – 30/2 Westjyotinagar Shahdara, Delhi, India – 110094
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Eureka Aventis Labs Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Eureka Aventis Labs Limited
FY 2025 filings availableEureka Aventis Labs Limited reported revenue of ₹65,000 for FY 2025.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹44,660 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹32,860 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 68.7% | ||||
| Net Profit Margin | 50.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Eureka Aventis Labs Limited, buy the company report.
Board of directors of Eureka Aventis Labs Limited
Eureka Aventis Labs has 5 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manish Kumar Agarwal | Director | 21 Oct 2005 | 21 Years 0 Months | Current |
| Nishant Garg | Director | 15 Apr 2021 | 5 Years 6 Months | Current |
| Ajay Kumar Gupta | Director | 21 Oct 2005 | 21 Years 0 Months | Current |
| Ashok Kumar Gupta | Director | 21 Oct 2005 | 21 Years 0 Months | Current |
| Prashant Garg Also directs: Wetwo Foods Private Limited, Eureka Homes Private Limited, Eureka Labs Limited and 5 more | Director | 15 Apr 2021 | 5 Years 6 Months | Current |
Peer comparison
Eureka Aventis Labs Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Toshi Biopharm Private Limited | ₹67,134 (FY 2025) | -99.0% | Delhi, India | |||
| Maze Medicare Private Limited | ₹66,925 (FY 2025) | Rohtak, Haryana, India | ||||
| Siddhaquest Pharmaceuticals Private Limited | ₹66,682 (FY 2021) | Chennai, Tamil Nadu, India | ||||
| Abhinav Drug Chem Private Limited | ₹66,532 (FY 2025) | 11.0% | Gujarat, India | |||
| Eureka Aventis Labs Limitedthis company | ₹65,000 (FY 2025) | ₹32,860 | 50.6% | Delhi, India | ||
| Avaomme Medicare Private Limited | ₹65,000 (FY 2024) | 242.0% | Kannauj, Uttar Pradesh, India | |||
| Aci Pharma Private Limited | ₹64,244 (FY 2024) | -94.0% | New Delhi, Delhi, India | |||
| R P Wires & Cables Private Limited | ₹63,127 (FY 2025) | -100.0% | Lucknow, Uttar Pradesh, India | |||
| Pushkar Pharmaceuticals Pvt Ltd | ₹63,000 (FY 2024) | 23.0% | Chandigarh, India | |||
| Emsons Pharmaceuticals Pvt Ltd | ₹62,450 (FY 2020) | 13.0% | Kolkata, West Bengal, India | |||
| Cellix Bio Private Limited | ₹61,900 (FY 2024) | -71.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Eureka Aventis Labs Limited, buy the company report.
Auditor
Eureka Aventis Labs Limited is audited by D GOEL ASSOCIATES for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| D GOEL ASSOCIATES | FY 2022 | 003595C |
Shareholding
The shareholding of Eureka Aventis Labs Limited is on record for 5 financial years, the latest being FY 2022, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Eureka Aventis Labs Limited, buy the company report.
Legal cases
No court or tribunal cases involving Eureka Aventis Labs Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Eureka Aventis Labs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Eureka Aventis Labs Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Eureka Aventis Labs Limited has 8 board changes on record since 2005: 5 appointments and 3 cessations. The latest: Nishant Garg ceased to be Additional Director on 11 Nov 2021.
Frequently asked questions
Eureka Aventis Labs is an active public limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 October 2005 (21+ years old) and is registered under CIN U24232DL2005PLC142039.
Eureka Aventis Labs has 5 current directors:
- Manish Kumar Agarwal - Director
- Nishant Garg - Director
- Ajay Kumar Gupta - Director
- Ashok Kumar Gupta - Director
- Prashant Garg - Director
The latest financial statements of Eureka Aventis Labs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Eureka Aventis Labs is U24232DL2005PLC142039. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Eureka Aventis Labs was incorporated on 21 October 2005, making it 21+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Eureka Aventis Labs by revenue are Toshi Biopharm Private Limited, Maze Medicare Private Limited, Siddhaquest Pharmaceuticals Private Limited, Abhinav Drug Chem Private Limited, Avaomme Medicare Private Limited and 5 more, all in the Pharma industry (Formulations).
Nishant Garg ceased to be Additional Director on 11 Nov 2021. Prashant Garg ceased to be Additional Director on 11 Nov 2021. Peeyush Kumar ceased to be Director on 22 Apr 2021. Eureka Aventis Labs has 8 board changes on record in total.
The registered office of Eureka Aventis Labs is at GF – 02 Groundfloor Eurekahouse A – 302 Westjyotinagar Shahdara, Delhi, India – 110094.
Eureka Aventis Labs operates in the pharma industry, in the drug formulation and development segment.
The compliance status of Eureka Aventis Labs is compliant as of 15 August 2026. The company is actively filing with the Registrar of Companies.
Eureka Aventis Labs can be reached at its registered office: GF – 02 Groundfloor Eurekahouse A – 302 Westjyotinagar Shahdara, Delhi, India – 110094.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
